Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

Inclusion Criteria: * • Patient has a confirmed diagnosis of MM according to the WHO 2022 classification (18) * Patient age is ≥ 18 years of age * Patient has a Relapsed or refractory disease as defined below: * Relapsed disease is defined as an initial response to previous treatment, followed by confirmed progressive disease by the International Myeloma Working Group (IMWG) (15) criteria \>60 days after cessation of treatment * Refractory disease is defined as failure to achieve a response or confirmed progressive disease by IMWG criteria (15) during previous treatment or ≤60 days after cessation of treatment. * Previous treatment with 1 or 2 lines of treatment (induction plus autologous stem cell transplant plus consolidation and maintenance has to be considered one single line) * Previous triple exposure that included an IMID, a PI, and an anti-CD38 antibody (patients with no response or relapse after front line therapy with Dara-VTD or Dara-VRD are eligible) * Progressive active symptomatic disease * Patient has measurable disease as defined by any of the following: * Serum M-protein level ≥0.5 g/dL; or * Urine M-protein level ≥200 mg/24 hours; or * Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio. * Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Able to adhere to the study visit schedule and all the other protocol procedures a…